title: [Efficacy of arterial infusion chemotherapy with neocarzinostatin on inoperable hepatoma].
abstract: The characteristic of a slow infusion technique of angiography provided a new method of selective intraarterial administration. We named this new method "high pressure one hot injection." When we tried to apply this method to patients with inoperable hepatoma, we considered that Neocarzinostatin (NCS) was a very applicable antitumor drug in terms of cell killing kinetics. Fifteen patients with inoperable hepatoma were treated with NCS by the selective intra-hepatic arterial infusion method. Administration of NCS was given by using a technique of high pressure one shot injection. The administration dose of NCS was 6000u. or 10000u., and 10 patients received once, and the others twice or three times. Results were as follows: 1) According to both Karnofsky's criteria and the criteria of direct response for solid cancer, an objective response was observed in 6 patients (40%). In proportion to the increase of the total dose and frequencies the individual efficacy increased. 2) The median survival was 5.5 months. 3) Decrease of serum AFP was seen, prominently within one month after injection. 4) The major side effects were fever (93%), liver dysfunctions (53%), leukopenia (46%), thrombocytopenia (33.3%), and their frequencies were related to the dose of one injection and that of the total. These results suggest that the high pressure one shot injection of NCS is very effective to inoperable hepatoma, but both dose and interval of injection remain to discussed.
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009353:Zinostatin / Q000008:administration & dosage*
chemical_list: D000903:Antibiotics, Antineoplastic; D009353:Zinostatin